JP2011510647A5 - - Google Patents

Download PDF

Info

Publication number
JP2011510647A5
JP2011510647A5 JP2010544739A JP2010544739A JP2011510647A5 JP 2011510647 A5 JP2011510647 A5 JP 2011510647A5 JP 2010544739 A JP2010544739 A JP 2010544739A JP 2010544739 A JP2010544739 A JP 2010544739A JP 2011510647 A5 JP2011510647 A5 JP 2011510647A5
Authority
JP
Japan
Prior art keywords
polynucleotide
composition
vector
mrna
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010544739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011510647A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/ES2009/000045 external-priority patent/WO2009095517A2/es
Publication of JP2011510647A publication Critical patent/JP2011510647A/ja
Publication of JP2011510647A5 publication Critical patent/JP2011510647A5/ja
Pending legal-status Critical Current

Links

JP2010544739A 2008-01-29 2009-01-29 遺伝子発現の転写後抑制を相乗的に生じさせることができる方法および組成物 Pending JP2011510647A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200800222 2008-01-29
PCT/ES2009/000045 WO2009095517A2 (es) 2008-01-29 2009-01-29 Métodos y composiciones capaces de provocar un silenciamiento post-transcripcional de la expresión génica de forma sinérgica

Publications (2)

Publication Number Publication Date
JP2011510647A JP2011510647A (ja) 2011-04-07
JP2011510647A5 true JP2011510647A5 (enExample) 2012-03-08

Family

ID=40807539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010544739A Pending JP2011510647A (ja) 2008-01-29 2009-01-29 遺伝子発現の転写後抑制を相乗的に生じさせることができる方法および組成物

Country Status (10)

Country Link
US (1) US20110030075A1 (enExample)
EP (1) EP2246432A2 (enExample)
JP (1) JP2011510647A (enExample)
CN (1) CN101981189A (enExample)
AU (1) AU2009209571A1 (enExample)
BR (1) BRPI0906657A2 (enExample)
CA (1) CA2713458A1 (enExample)
MX (1) MX2010008326A (enExample)
RU (1) RU2010136040A (enExample)
WO (1) WO2009095517A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9441221B2 (en) 2007-03-30 2016-09-13 Rutgers, The State University Of New Jersey Compositions and methods for gene silencing
US8343941B2 (en) 2007-03-30 2013-01-01 Rutgers, The State University Of New Jersey Compositions and methods for gene silencing
US8907075B2 (en) 2007-03-30 2014-12-09 Samuel Ian Gunderson Compositions and methods for gene silencing
WO2012045894A1 (es) * 2010-10-05 2012-04-12 Proyecto De Biomedicina Cima, S.L. Compuestos y composiciones para el tratamiento de enfermedades debidas a la infección por el virus de la hepatitis b
US9862945B2 (en) * 2013-04-20 2018-01-09 Research Institute At Nationwide Children's Hospital Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs
EP2853595A1 (en) * 2013-09-30 2015-04-01 Soluventis GmbH NOTCH 1 specific siRNA molecules
CN107746857B (zh) * 2017-08-07 2021-02-05 中国农业大学 一种抑制基因表达的rna干扰方法
CN108893487A (zh) * 2018-07-19 2018-11-27 中国农业科学院北京畜牧兽医研究所 一种含有C-Myc蛋白融合标签的植物表达质粒载体及其载体的构建方法
JP2022524383A (ja) * 2019-03-08 2022-05-02 ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー ハンチントン病を処置するための組成物および方法
EP4004204A1 (en) 2019-07-23 2022-06-01 Oxford BioMedica (UK) Limited Enhancing production of lentiviral vectors
CN114159459A (zh) * 2021-12-20 2022-03-11 塔里木大学 miR-26a在制备治疗子宫内膜炎的药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3626187B2 (ja) 1993-06-07 2005-03-02 バイカル インコーポレイテッド 遺伝子治療に適するプラスミド
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US6692910B2 (en) 1997-07-28 2004-02-17 The University Of Connecticut Inhibition of a target messenger RNA with a modified U1 small nuclear RNA
EP1384784A1 (en) * 2001-03-30 2004-01-28 Instituto Cientifico Y Tecnologico De Navarra, S.A. Method for reversible inhibition of gene expression by modified ribonucleoproteins
EP2428570B1 (en) 2001-09-28 2018-05-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
CA2524569C (en) 2002-05-03 2013-10-22 Duke University A method of regulating gene expression
WO2005026322A2 (en) 2003-09-11 2005-03-24 Clontech Laboratories, Inc. siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME
US20080131940A1 (en) 2004-06-25 2008-06-05 Robert Chiu Target Cell-Specific Short Interfering Rna and Methods of Use Thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
PT3272872T (pt) 2005-10-20 2020-06-26 Uniqure Ip Bv Vetores aav melhorados produzidos em células de insetos
EP1969000A2 (en) 2005-12-06 2008-09-17 Centre National de la Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2007148971A2 (en) 2006-06-21 2007-12-27 Amsterdam Molecular Therapeutics B.V. Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells
GB0701722D0 (en) * 2007-01-30 2007-03-07 Scottish Crop Res Inst Inhibition of gene expression

Similar Documents

Publication Publication Date Title
RU2010136040A (ru) Композиции, способные синергично вызывать посттранскрипционный сайленсинг экспрессии генов, и способы их применения
Swaminathan et al. MicroRNAs and HIV-1 infection: antiviral activities and beyond
JP2014505045A5 (enExample)
Bao et al. LncRNA DBH-AS1 facilitates the tumorigenesis of hepatocellular carcinoma by targeting miR-138 via FAK/Src/ERK pathway
WO2017027350A3 (en) Rnai therapy for hepatitis b virus infection
WO2013074974A3 (en) Modified rnai agents
TN2013000366A1 (en) Viral inhibitor composition for in vivo therapeutic use
EA201490654A1 (ru) Новые ингибиторы вирусной репликации
MY160130A (en) Hepatitis c virus inhibitors
JP2011528713A5 (enExample)
JP2017158561A5 (enExample)
JP2018533954A5 (enExample)
EA201301158A1 (ru) Противовирусные соединения
EA201200890A1 (ru) Комбинированная терапия hcv
JP2018536689A5 (enExample)
EA201000085A1 (ru) dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ
JP2017503820A5 (enExample)
JP2015519891A5 (enExample)
JP2011116755A5 (enExample)
JP2018519835A5 (enExample)
EA201171376A1 (ru) Производные тиено[2,3-b]пиридина в качестве ингибиторов репликации вируса
JP2011121944A5 (enExample)
JP2017531673A5 (enExample)
WO2019217397A3 (en) Compositions and methods for improving strand biased
JP2012505657A5 (enExample)